Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Revenue

In the year 2023, Lineage Cell Therapeutics had annual revenue of $8.95M, a decrease of -39.16%. Revenue in the quarter ending December 31, 2023 was $2.09M with 9.03% year-over-year growth.

• Revenue (ttm): $8.95M
• Revenue Growth: -39.16%
• P/S Ratio: 22.37
• Revenue / Employee: $131,544
• Employees: 68
• Market Cap: 200.13M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	8.95M	-5.76M	-39.16%
Dec 31, 2022	14.70M	10.36M	238.70%
Dec 31, 2021	4.34M	2.52M	137.73%
Dec 31, 2020	1.83M	-1.69M	-48.05%
Dec 31, 2019	3.52M	-1.47M	-29.53%
Dec 31, 2018	4.99M	1.53M	44.25%
Dec 31, 2017	3.46M	-2.47M	-41.62%
Dec 31, 2016	5.92M	-1.11M	-15.82%
Dec 31, 2015	7.04M	1.79M	34.17%
Dec 31, 2014	5.24M	810.00K	18.27%
Dec 31, 2013	4.43M	518.67K	13.25%
Dec 31, 2012	3.92M	-518.83K	-11.70%
Dec 31, 2011	4.43M	726.14K	19.58%
Dec 31, 2010	3.71M	1.78M	92.61%
Dec 31, 2009	1.93M	421.38K	28.02%
Dec 31, 2008	1.50M	457.67K	43.75%
Dec 31, 2007	1.05M	-115.89K	-9.97%
Dec 31, 2006	1.16M	258.82K	28.66%
Dec 31, 2005	903.20K	214.82K	31.21%
Dec 31, 2004	688.38K	131.96K	23.71%
Dec 31, 2003	556.42K	169.40K	43.77%
Dec 31, 2002	387.02K	235.10K	154.76%
Dec 31, 2001	151.92K	99.43K	189.41%
Dec 31, 2000	52.49K	-985.01K	-94.94%
Dec 31, 1999	1.04M	-112.50K	-9.78%
Jun 30, 1998	1.15M	1.09M	1,740.00%
Dec 31, 1997	62.50K	-	-
Dec 31, 1996	0	-	-
Jun 30, 1995	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.